Disease or Syndrome – Page 76

Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome

10 months ago talkbio0Tagged Clinical Research, Cognitive Improvement, EMPEROR, Infantile Severe Myoclonic Epilepsy, Phase 3 trial, regulatory, Seizures, Zorevunersen

Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment

Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings

10 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, Chronic disease, Confirmation, Hearings, public health policy, Robert F. Kennedy, Secretary Nomination, Senate, Skepticism, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

10 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

10 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

10 months ago talkbio0Tagged Coleman, Commercial Officer, Eli, Eli Lilly, Jamie, Kailera, Obesity, Zepbound

Kailera Therapeutics, Jamie Coleman, Chief Commercial Officer, Obesity Treatment, Zepbound, Eli Lilly

Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales

10 months ago talkbio0Tagged Clinical Trials, DMD, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Projections, Sales - occupational activity

Sarepta Therapeutics, ELEVIDYS, Duchenne Muscular Dystrophy (DMD), Gene Therapy, Clinical Trial Results, Sales Projections

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

10 months ago talkbio0Tagged AK006, Allakos, chronic, Clinical Trials, Dermatitis, Atopic, Failure (biologic function)

Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis

Pfizer Agrees to $60 Million Settlement Over Nurtec Anti-Kickback Allegations

10 months ago talkbio0Tagged anti-kickback suit, Migraine Disorders, Nurtec, Pfizer, settlement

Pfizer, Nurtec, anti-kickback suit, settlement, Biohaven, migraine medicine

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

10 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

10 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.